Obesity drug 'mediator' likely responsible for thousands of hospitalizations and deaths in France (Medical News Today, 10 February 2012)

Atlanta anti-obesity ads 'risk child stigma' (BBC News Online, 9 February 2012)

Analysis of updated ALSYMPCA phase III data confirms overall survival benefit of Alpharadin in castration-resistant prostate cancer patients with bone metastases (Reuters, 10 February 2012)

10 Feb 2012

Norway-based Algeta ASA has announced completion of a phase III trial evaluating Alpharadin (radium-223 chloride) in patients with castration-resistant prostate cancer and bone metastases.

Share this story

Top stories

Call for nominations for Awards Committee Chair
30 Oct 2024

James M Tanner Award - 2025 nominations open
30 Oct 2024

Would you like to host the BSPED annual meeting?
21 Oct 2024

Most read